1. Search Result
Search Result
Results for "

145

" in MedChemExpress (MCE) Product Catalog:

297

Inhibitors & Agonists

2

Screening Libraries

5

Fluorescent Dyes

6

Biochemical Assay Reagents

18

Peptides

113

Inhibitory Antibodies

28

Natural
Products

31

Recombinant Proteins

11

Isotope-Labeled Compounds

24

Antibodies

1

Click Chemistry

28

Oligonucleotides

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108360
    PDD 00017273
    20+ Cited Publications

    Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    PDD 00017273 is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG), with an IC50 of 26 nM, and a KD of 1.45 nM .
    PDD 00017273
  • HY-B0185
    Lidocaine
    20+ Cited Publications

    Lignocaine

    Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine
  • HY-17044
    Duvelisib
    15+ Cited Publications

    IPI-145; INK1197

    PI3K Cancer
    Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively .
    Duvelisib
  • HY-P9930
    Evolocumab
    3 Publications Verification

    AMG 145

    NF-κB Ser/Thr Protease Toll-like Receptor (TLR) Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
    Evolocumab
  • HY-N0610A
    Cinnamic acid
    3 Publications Verification

    3-Phenylacrylic acid; β-Phenylacrylic acid

    Environmental Pollutants Endogenous Metabolite Cancer
    Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
    Cinnamic acid
  • HY-B0185A
    Lidocaine hydrochloride
    20+ Cited Publications

    Lignocaine hydrochloride

    Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence . Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor .
    Lidocaine hydrochloride
  • HY-N0083
    Betulin
    Maximum Cited Publications
    15 Publications Verification

    Trochol

    Fatty Acid Synthase (FASN) Apoptosis Endogenous Metabolite Cancer
    Betulin (Trochol), is a sterol regulatory element-binding protein (SREBP) inhibitor with an IC50 of 14.5 μM in K562 cell line .
    Betulin
  • HY-103642A

    Inositol 1,4,5-trisphosphate trisodium; Ins(1,4,5)-P3 trisodium

    Calcium Channel Metabolic Disease
    D-myo-Inositol-1,4,5-triphosphate sodium salt is the trisodium salt of D-myo-Inositol 1,4,5-trisphosphate (1,4,5-IP3), which is a second messenger that stimulates the discharge of calcium from the endoplasmic reticulum.
    D-myo-Inositol-1,4,5-triphosphate trisodium
  • HY-101507
    Zerencotrep
    10+ Cited Publications

    Pico145; HC-608

    TRP Channel Cancer
    Pico145 (HC-608) is a remarkable inhibitor of TRPC1/4/5 channels, inhibits (-)-englerin A-activated TRPC4/TRPC5 channels, with IC50s of 0.349 and 1.3 nM in cells, and shows no effect on TRPC3, TRPC6, TRPV1, TRPV4, TRPA1, TRPM2, TRPM8 .
    Zerencotrep
  • HY-W017982

    CMI/MI

    Environmental Pollutants Bacterial Reactive Oxygen Species (ROS) p38 MAPK Mitochondrial Metabolism Infection Neurological Disease Inflammation/Immunology
    CMIT/MIT is a CMIT and MIT mixture. CMIT and MIT are powerful synthetic biocidal substances. CMIT and MIT are used as preservatives in various cosmetics and industrial products. CMIT and MIT are present in many water-soluble consumer products, such as shampoos, toothpastes. CMIT/MIT (3:1 mixture of CMIT and MIT) produces mitochondrial ROS via inhibiting mitochondrial complex I and II. CMIT/MIT (in 3:1 ratio) induces neurotoxicity through the upregulation of the MAPKs signaling pathways. CMIT/MIT can be used in the research of respiratory diseases and neuroblastoma .
    CMIT/MIT (14.5% in water)
  • HY-150168

    Bacterial Infection
    TH-Z145, a lipophilic bisphosphonate, is a FPPS inhibitor (IC50: 210 nM) .
    TH-Z145
  • HY-B0185B
    Lidocaine hydrochloride hydrate
    15+ Cited Publications

    Lignocaine hydrochloride hydrate

    Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine hydrochloride hydrate
  • HY-15755
    RKI-1447
    4 Publications Verification

    ROCK Cancer
    RKI-1447 is a potent small molecule inhibitor of ROCK1 and ROCK2 with IC50 values of 14.5 nM and 6.2 nM, respectively.
    RKI-1447
  • HY-P990802

    CD3 Metabolic Disease Inflammation/Immunology
    Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector T cells and improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .
    Anti-Mouse CD3ε Antibody (145-2C11)
  • HY-107536
    ML 145
    1 Publications Verification

    GPR35 CXCR Inflammation/Immunology Endocrinology
    ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM) . ML 145 has no significant activity for GPR35 at either rodent ortholog .
    ML 145
  • HY-15779A
    K145 hydrochloride
    5+ Cited Publications

    SphK Apoptosis Cancer
    K145 hydrochloride is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 μM and a Ki of 6.4 μM. K145 hydrochloride is inactive against SphK1 and other protein kinases. K145 hydrochloride induces cell apoptosis and has potently antitumor activity .
    K145 hydrochloride
  • HY-141514
    MSA-2 dimer
    1 Publications Verification

    STING Inflammation/Immunology Cancer
    MSA-2 dimer is a selective, orally active non-nucleotide STING agonist (Kd=145 μM) with long-term antitumor and immunogenic activity. MSA-2 dimer is bound to STING as a non-covalent dimer exhibiting higher permeability than cyclic dinucleotide .
    MSA-2 dimer
  • HY-17044A

    IPI-145 R enantiomer; INK1197 R enantiomer

    PI3K Cancer
    Duvelisib R enantiomer is a PI3K inhibitor, which is the less active enantiomer of Duvelisib.
    Duvelisib (R enantiomer)
  • HY-B0185S1

    Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine-d10
  • HY-16694
    BAMB-4
    1 Publications Verification

    ITPKA-IN-C14

    Phosphatase Cancer
    BAMB-4 (ITPKA-IN-C14) is a specific and membrane-permeable ITPKA inhibitor. BAMB-4 has high stability and membrane permeability and against the inositol-1,4,5-trisphosphate (InsP3) kinase activity of inositol-1,4,5-trisphosphate-3-kinase A (ITPKA) with an IC50 value of 20 μM. BAMB-4 can be used for the research of metastasis of lung cancer .
    BAMB-4
  • HY-P990284

    C-type Lectin-like Receptors (CTLRs) Metabolic Disease Inflammation/Immunology Cancer
    Anti-Mouse CD205 Antibody (NLDC-145) is a rat-derived IgG2aκ type antibody inhibitor, targeting to mouse CD205. Anti-Mouse CD205 Antibody (NLDC-145) reacts with CD205 also known as DEC-205. Anti-Mouse CD205 Antibody (NLDC-145) can be used for the researches of cancer, inflammation, immunology and metabolic disease, such as colitis, D2F2/E2 tumor and diabetes .
    Anti-Mouse CD205 Antibody (NLDC-145)
  • HY-R00282

    MicroRNA Cancer
    hsa-miR-145-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-145-5p mimic
    hsa-miR-145-5p mimic
  • HY-N9686

    Others Others Inflammation/Immunology
    Caffeoyl-CoA is a substrate of Chalcone synthase derived from rye with a Km value of 1.45 μM .
    Caffeoyl-CoA
  • HY-B0185AS

    Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine-d10 (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence . Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia .
    Lidocaine-d10 hydrochloride
  • HY-136975

    Caspase Neurological Disease Metabolic Disease
    Caspase-3-IN-1 (compound 11b) is a potent Caspase-3 inhibitor, with an IC50 of 14.5 nM .
    Caspase-3-IN-1
  • HY-B0185R
    Lidocaine (Standard)
    15+ Cited Publications

    Lignocaine (Standard)

    Reference Standards Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine (Standard) is the analytical standard of Lidocaine. This product is intended for research and analytical applications. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine (Standard)
  • HY-RI00282

    MicroRNA Cancer
    hsa-miR-145-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-145-5p inhibitor
    hsa-miR-145-5p inhibitor
  • HY-103642

    Inositol 1,4,5-trisphosphate hexapotassium salt; Ins(1,4,5)-P3 hexapotassium salt

    Calcium Channel Metabolic Disease
    D-myo-Inositol 1,4,5-trisphosphate hexapotassium salt is the hexapotassium salt of D-myo-Inositol 1,4,5-trisphosphate (1,4,5-IP3), which is a second messenger that stimulates the discharge of calcium from the endoplasmic reticulum.
    D-myo-Inositol 1,4,5-trisphosphate hexapotassium salt
  • HY-133690

    Calcium Channel Metabolic Disease
    D-myo-Inositol-1,3,4,5-tetraphosphate sodium is formed by the phosphorylation of Ins(1,4,5)P3 by inositol 1,4,5-triphosphate 3-kinase.
    D-myo-Inositol-1,3,4,5-tetraphosphate sodium
  • HY-B0365AS

    Cytochrome P450 iGluR Autophagy Neurological Disease
    Memantine-d6 (hydrochloride) is the deuterium labeled Memantine hydrochloride. Memantine (hydrochloride) (D-145 (hydrochloride)) is a moderate affinity, uncompetitive NMDA receptor antagonist, inhibit CYP2B6 and CYP2D6 with Kis of 0.51 nM and 94.9 μM, respectively .
    Memantine-d6 hydrochloride
  • HY-P99760

    BCD-145

    CTLA-4 Cancer
    Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
    Nurulimab
  • HY-17044R

    IPI-145 (Standard); INK1197 (Standard)

    PI3K Reference Standards Cancer
    Duvelisib (Standard) is the analytical standard of Duvelisib. This product is intended for research and analytical applications. Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively .
    Duvelisib (Standard)
  • HY-W795960

    Biochemical Assay Reagents Calcium Channel Phospholipase Neurological Disease Metabolic Disease
    D-myo-inositol 1,4,5-trisphosphate sodium salt is a widely distributed intracellular second messenger. D-myo-inositol 1,4,5-trisphosphate sodium salt acts as a potent agonist of the Ins (1,4,5) P3 receptor with an EC50 of 0.12 μM and inhibits bovine PLC-δ1, with an IC50 of 5.4 μM for binding and an IC50 of 12.4 μM for hydrolysis. D-myo-inositol 1,4,5-trisphosphate sodium saltis metabolized into Ins (1,4) P2 and Ins (1,3,4,5) P4. D-myo-inositol 1,4,5-trisphosphate sodium salt mediates various cellular processes, including growth, development, fertilization, secretion, contraction and neuromodulation. D-myo-inositol 1,4,5-trisphosphate sodium salt inhibits PIP2 hydrolysis and Ca 2+-ATPase activity. D-myo-inositol 1,4,5-trisphosphate sodium salt is used for cardiac preconditioning, exerts cardioprotective effects and mimics ischemic preconditioning. D-myo-inositol 1,4,5-trisphosphate sodium salt is applied in studies related to intracellular calcium and phosphoinositol signaling pathways .
    D-myo-Inositol 1,4,5-trisphosphate sodium salt
  • HY-B0185AS1

    Lignocaine-d6 hydrochloride

    Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine-d6 (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence . Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor .
    Lidocaine-d6 hydrochloride
  • HY-105128

    WIN 32729

    3β-HSD Endocrinology
    Epostane (WIN 32729) is an orally active inhibitor for 3β-hydroxysteroid dehydrogenase, with IC50 of 1.45 nM. Epostane blocks ovulation and pregnancy in rats .
    Epostane
  • HY-N8331

    Endogenous Metabolite Acyltransferase Metabolic Disease
    Terpendole I is a fungal indole diterpenoid and an ACAT inhibitor (IC50 = 145 µM). Terpendole I can be used in studies related to lipid metabolism .
    Terpendole I
  • HY-15779

    SphK Apoptosis Cancer
    K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM. K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity .
    K145
  • HY-R00281

    MicroRNA Cancer
    hsa-miR-145-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-145-3p mimic
    hsa-miR-145-3p mimic
  • HY-111389

    FAAH Autophagy Metabolic Disease
    FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC50s of 145 nM and 650 nM for rat and human FAAH, respectively.
    FAAH-IN-1
  • HY-175243

    Adenosine Deaminase Apoptosis Cancer
    ADAR1-IN-1 is a potent ADAR1 inhibitor. ADAR1-IN-1 significantly suppressed DU-145 cell proliferation (IC50 = 1.11 μM), clonogenicity, migration, and invasion, arrests cell cycle, and induces apoptosis. ADAR1-IN-1 safely and effectively inhibits tumor growth. ADAR1-IN-1 can be used for the study of prostate cancer (PCa) .
    ADAR1-IN-1
  • HY-P10345

    Bacterial Infection
    OP-145, an cathelicidin LL-37 derivative, is an antimicrobial peptide, and shows antibacterial activity against several MRSA strains. OP-145 can be used for research of chronic suppurative otitis media .
    OP-145
  • HY-122888

    PI3K FGFR Autophagy CDK Reactive Oxygen Species (ROS) Cancer
    MPT0L145 is a PIK3C3/FGFR inhibitor, with a Kd value of 0.53 nM for PIK3C3. MPT0L145 decreases the phosphorylation of FGFR1, FGFR3 and their downstream proteins (FRS2, ERK and Akt). MPT0L145 induces G0/G1 cell cycle arrest and decreased protein levels of cyclin E. MPT0L145 promotes mitochondrial dysfunction, ROS production, and DNA damage. MPT0L145 is an autophagy inhibitor. MPT0L145 significantly sensitizes cancer cells to targeted or chemotherapeutic agents. MPT0L145 can be used for cancer research, such as bladder cancer and NSCLC .
    MPT0L145
  • HY-160129

    ML-970; AS-I-145; NSC 716970

    Nucleoside Antimetabolite/Analog Cancer
    Centanamycin (ML-970; AS-I-145; NSC 716970) is a novel DNA-binding agent, and shows cytotoxic activity, with an average GI50 of 34 nM in NCI-60 cell line screening .
    Centanamycin
  • HY-149415

    RET FGFR VEGFR c-Kit c-Met/HGFR PDGFR Raf Cancer
    Multi-kinase-IN-5 (compound 15c) is a promising multi-kinase inhibitory agent. Multi-kinase-IN-5 inhibits a panel of protein kinases (RET, KIT, cMet, VEGFR1,2, FGFR1, PDGFR and BRAF), showing % inhibition of 74%, 31%, 62%, 40%, 73%, 74%, 59%, and 69%, respectively, and IC50 of 1.287, 0.117 and 1.185 μM against FGFR1, VEGFR, and RET kinases, respectively .
    Multi-kinase-IN-5
  • HY-P10992

    PI3K Akt mTOR Caspase Apoptosis Bcl-2 Family Cancer
    YVPGP is an oligopeptide exacted from Anthopleura anjunae. YVPGP has a significant antitumor activity by mediating PI3K/AKT/mTOR signaling pathway. YVPGP arrests DU-145 cells in the S phase and induces apoptosis via mitochondrial and death receptor pathways (caspase3, 7, 8, 9). YVPGP effectively inhibits tumor growth in DU-145 xenografts mice model, promising for prostate cancer research .
    YVPGP
  • HY-B0185S

    Isotope-Labeled Compounds Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    N-Oxide Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine-d10 N-Oxide
  • HY-W037980

    PROTAC Linkers Metabolic Disease Cancer
    Succinamic acid is a weak inhibitor for human LL-xylose reductase with an IC50 of 1.45 mM. Succinamic acid can be used as a linker for synthesis of CQ-16 (HY-169336) .
    Succinamic acid
  • HY-N15449

    HSP Caspase Apoptosis Reactive Oxygen Species (ROS) Bcl-2 Family Cancer
    Vicanicin is a depsidone compound found in lichens. Vicanicin inhibits the expression of Hsp70, regulates the redox-sensitive mechanisms within cells, promotes the increase of reactive oxygen species (ROS) in cancer cells, changes the Bax/Bcl-2 ratio, activates caspase-3, and triggers apoptosis. Vicanicin inhibits cell growth and induces apoptosis in androgen-sensitive (LNCaP) and androgen-insensitive (DU-145) human prostate cancer cells. Vicanicin is promising for research of prostate cancer .
    Vicanicin
  • HY-B0185G

    Lignocaine

    Apoptosis Sodium Channel MEK ERK NF-κB Cancer
    Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine
  • HY-171252

    EGFR Cancer
    EGFR-IN-145 (compound 7c) is an EGFR kinase inhibitor. At a concentration of 20 μM, EGFR-IN-145 has an inhibition rate of 52.7% on EGFR-wild type kinase .
    EGFR-IN-145

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: